Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6812-6819

  Marri, Preethi Reddy ^a   Hodge, Lucy S ^a   Maurer, Matthew J ^a   Ziesmer, Steven C ^a   Slager, Susan L ^a   Habermann, Thomas M ^a   Link, Brian K ^b   Cerhan, James R ^a   Novak, Anne J ^a   Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD30 ANTIGEN; CHEMOKINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PREDNISONE; PROCARBAZINE; SCATTER FACTOR; THYMUS AND ACTIVATION RELATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-2;

EID: 84890675944     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1879     Document Type: Article

References (23)

1. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Ana-gnostopoulos I, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95:1443-50. (Pubitemid 30099859)
2. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3-13. (Pubitemid 351347529)
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodg-kin's Disease. N Engl J Med 1998;339:1506-14.
4. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55:162-76. (Pubitemid 34250900)
5. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97. (Pubitemid 34627193)
6. Vener C, Guffanti A, Pomati M, Colombi M, Alietti A, La Targia ML, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 2000;37: 333-9. (Pubitemid 30162543)
7. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 2002;118:195-201. (Pubitemid 34779537)
8. Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005;65:5516-9. (Pubitemid 40911150)
9. Rautert R, Schinkothe T, Franklin J, Weihrauch M, Boll B, Pogge E, et al. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008;49:2091-8.
10. Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, Cockburn MG, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004;103: 3216-21. (Pubitemid 38451701)
11. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 2008;14:6974-8.
12. Glass G, Papin JA, Mandell JW. SIMPLE: a sequential immunoperox-idase labeling and erasing method. J Histochem Cytochem 2009;57: 899-905.
13. Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002;13:1908-14. (Pubitemid 36040779)
14. Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009;125: 1092-101.
15. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009;27: 31-9.
16. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104: 13134-9. (Pubitemid 351737605)
17. Aldinucci D, Lorenzon D, Olivo K, Rapana B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Stern-berg cells. Leuk Lymphoma 2004;45:1731-9. (Pubitemid 38997138)
18. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 2012;30:3383-8.
19. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 1997;102: 21-8. (Pubitemid 27089983)
20. Brown RE, Shah NR, Lobel JS, George BA, Gaylord H, Simonich WL. Interleukin-6-associated laboratory parameters and immu-nohistochemistry in symptomatic stage A and B nodular scle-rosing Hodgkin's disease in children. Ann Clin Lab Sci 1997; 27:26-33. (Pubitemid 27030200)
21. Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995;6:477-82.
22. Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, et al. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol 1991;2(Suppl 2):43-7.
23. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ, et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lympho-ma. Blood 2011;118:2809-20.